Targeting NOTCH1 in combination with antimetabolite drugs prolongs life span in relapsed pediatric and adult T-acute lymphoblastic leukemia xenografts

• Published in: Experimental hematology & oncology 2023-09, Vol.12 (1), p.1-76, Article 76
• Main Authors: Minuzzo, Sonia, Agnusdei, Valentina, Pinazza, Marica, Amaro, Adriana A, Sacchetto, Valeria, Pfeffer, Ulrich, Bertorelle, Roberta, Spinelli, Orietta, Serafin, Valentina, Indraccolo, Stefano
• Format: Article
• Language: English
• Subjects: Acute lymphocytic leukemia; Analysis; anti-NOTCH1; Antibodies; Antimetabolites; Biological products; Cancer; Chemotherapy; Correspondence; Drugs; Health aspects; Leukemia; Ligases; Metabolism; Mice; Monoclonal antibodies; Mutation; Pediatrics; Relapse; Spleen; T cells; T-ALL; Vincristine
• ISSN: 2162-3619; 2162-3619
• DOI: 10.1186/s40164-023-00439-6

T-cell acute lymphoblastic leukemia (T-ALL) is a hematologic tumor, characterized by several genetic alterations, that constitutes 15% of pediatric and 25% of adult ALL. While with current therapeutic protocols children and adults' overall survival (OS) rates reach 85-90% and 40-50%, respectively, the outcome for both pediatric and adult T-ALL patients that relapse or are refractory to induction therapy, remains extremely poor, achieving around 25% OS for both patient groups. About 60% of T-ALL patients show increased NOTCH1 activity, due to activating NOTCH1 mutations or alterations in its ubiquitin ligase FBXW7. NOTCH signaling has been shown to contribute to chemotherapy resistance in some tumor models. Hence, targeting the NOTCH1 signaling pathway may be an effective option to overcome relapsed and refractory T-ALL. Here, we focused on the therapeutic activity of the NOTCH1-specific monoclonal antibody OMP-52M51 in combination either with drugs used during the induction, consolidation, or maintenance phase in mice xenografts established from pediatric and adult relapsed NOTCH1 mutated T-ALL samples. Interestingly, from RNAseq data we observed that anti-NOTCH1 treatment in vivo affects the purine metabolic pathway. In agreement, both in vitro and in vivo, the greatest effect on leukemia growth reduction was achieved by anti-NOTCH1 therapy in combination with antimetabolite drugs. This result was further corroborated by the longer life span of mice treated with the anti-NOTCH1 in combination with antimetabolites, indicating a novel Notch-targeted therapeutic approach that could ameliorate pediatric and adult T-ALL patients outcome with relapse disease for whom so far, no other therapeutic options are available. Keywords: T-ALL, Relapse, anti-NOTCH1, Antimetabolites